Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha

Hepato-Gastroenterology

Volumn 54, Issue 78, 2007, Pages 1761-1765

  Christodoulou, Dimitrios ^a   Christou, Leonidas ^a   Zervou, Eleftheria ^b   Katsanos, Konstantinos ^a   Kitsanou, Margarita ^a   Tsianos, Epameinondas V ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Antiplatelet antibodies; Chronic hepatitis B; Chronic hepatitis C; Thrombocytopenia

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE ANTIBODY;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; ANTIBODIES; AUTOANTIBODIES; BLOOD PLATELETS; CELL ADHESION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPATITIS B; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; MALE; MIDDLE AGED; SPLEEN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 35948991120     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Stoffa R, Burgess SJ, Peters M: Clinical pharmacology of antiviral agents. In: Zakim D, Boyer TD (Eds.). Hepatology - a Textbook of Liver Diseases. Philadelphia: Saunders, 1996; pp. 1293-1299.
2. Peters M: Mechanism of action of interferons. Semin Liv Dis 1989; 9:235-239.
3. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al: Long-term follow up of HBeAg positive patients treated with interferon-a for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427.
4. Fattovich G, McIntyre G, Thursz M, Colman K, Giuliano G, Alberti A, et al: Hepatitis B virus precore/core variation and interferon therapy. Hepatology 1995; 22:1355-1362.
5. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
6. Davis GL, Esteban-Mur R, Rustgi VK, Hoefs J, Gordon SC, Trepo C, et al: Interferon a-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493-1499.
7. Reddy KR, Wright TL, Pockros PJ, Schiffman ML, Everson G, Reindolallar R, et al: Efficacy and safety of pegylated (40-kd) inteferon a-2a compared with interferon a-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
8. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, et al: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
9. Renault PF, Hoofnagle JH: Side effects of alpha interferon. Semin Liv Dis 1989; 9:283-287.
10. Zoumbos NC, Djeu JY, Young NS: Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 1984; 133:769-774.
11. Shrestha R, McKinley C, Bilir BM, Everson GT: Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995; 90:1146-1147.
12. Murakami CS, Zeller K, Bodenheimer HCJ, Lee WM: Idiopathic thrombocytopenic purpura during interferon-alpha-2b treatment for chronic hepatitis. Am J Gastroenterol 1994; 89:2244-2245.
13. Takase K, Nakano T, Hamada M, Shiraki K, Oohashi Y, Kihira T, et al: Hemolytic anemia provoked by recombinant alpha-interferon. J Gastroenterol 1995; 30:795-797.
14. Hirashima N, Mizokami M, Orito E, Yamauchi M, Narita M, Mizuno M, et al: Platelet antibodies in patients with chronic liver disease. Intern Med 1994; 33:300-302.
15. Pereira G, Accatino L, Alfaro J, Brahm J, Higalgo P, Mezzano D: Platelet antibodies in patients with chronic liver disease. Am J Haematol 1995; 50:173-178.
16. Feistauer SM, Penner E, Mayr WR, Panzer S: Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 1997; 25:1343-1345.
17. De Noronha R, Taylor BA, Wild G, Triger DR, Greaves M: Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and the severity of liver disease. Clin Lab Haematol 1991; 13:127-135.
18. Graber D, Giuliani D, Leevy CM, et al: Platelet associated IgG in hepatitis and cirrhosis. J Clin Immunol 1984; 4:109-111.
19. Juji T, Kano K, Milgrom F: Mixed agglutination with platelets. Int Archs Allergy Appl Immunol 1972; 42:474-484.
20. Shibata Y, Juji T, Nishizawa Y, Sakamoto H, Ozawa N: Detection of platelet antibodies by a newly developed mixed agglutination with platelets. Vox Sang 1981; 41:25-31.
21. Rachel JM, Sinor LT, Tawtik OW, Summer TC, Beck ML, Bayer WL, et al: A solid-phase red cell adherence test for platelet crossmatching. Med Lab Sci 1985; 42:194-195.
22. Jones CD, Gould LM, Lee S: An evaluation of solid phase red cell adherence test for detecting of platelet-associated IgG in immune thrombocytopenia. Am J Clin Pathol 1990; 93:552-554.
23. von der Borne AE, Helmerhorst FM, van Leeuwen EF, Pegels HG, von Riesz E, Engelfriet CP: Autoimmune thrombocytopenia: detection of platelet autoantibodies with the suspension immunofluorescence test. Br J Haematol 1980; 45:319-327.
24. Hacker-Shanin B, Giannitsis DJ: A comparison of a solid phase IRC assay and the PSIFT for detection of antibodies to platelets. Cytobios 1992; 70:63-68.
25. Leach MF, Cooper LK, AuBuchon JP: Detection of drug-dependent platelet antibodies by use of solid-phase red cell adherence techniques. Immunohematology 1995; 11:143-149.
26. Rachel JM, Summer TC, Sinor LT, Plapp FV: Use of a solid phase red cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988; 90:63-68.
27. Landolfi R, Leone G, Fedeli G, Storti S, Laghi F, Bizzi B: Platelet associated IgG in acute and chronic hepatic diseases. Scan J Haematol 1980; 25:417-422.
28. Barrison IG, Knight ID, Viola MA, Murray-Lyon IM, Mitchell TR: Platelet associated immunoglobulins in chronic liver disease. Br J Haematol 1981; 48:347-350.
29. Pfueller SL, Firkin BG, Kerlero de Bosbo N, Riglar A, Mackay IR: Association of increased immune complexes, platelet IgG and serum IgG in chronic active hepatitis. Clin Exp Immunol 1983; 54:655-660.
30. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, et al: A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37:1267-1276.
31. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y: Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmmune thrombocytopenia. Am J Med 2003; 114:322-325.
32. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y: Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168:3675-3682.
33. Kuwana M, Kaburaki J, Ikeda Y: Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998; 102:1393-1402.
34. Toghill PJ, Green S: Haematological changes in active chronic hepatitis with reference to the role of the spleen. J Clin Pathol 1975; 28:8-11.
35. Mueller-Eckhardt C, Mueller-Eckhardt G, Kayser W, Voss RM, Wegner J, Kuenzlen E: Platelet associated IgG, platelet survival and platelet sequestration in thrombocytopenic states. Br J Haematol 1982; 52:49-58.
36. Gomez F, Ruiz P, Shreiber AD: Impaired function of macrophage Fc receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994; 331:1122-1228.
37. McMillan R: Clinical role of antiplatelet assays. Semin Thromb Hemost 1995; 21:37-45.
38. Dourakis SP, Deutsch M, Hadziyannis SJ: Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996; 25:972-975.
39. Tappero G, Negro F, Farina M, Gallo M, Angeli A, Hadengue A: Safe switch to beta-interferon treatment of chronic hepatitis C after alpha-interferon-induced autoimmune thrombocytopenia. J Hepatol 1996; 25:270.
40. Khan HA, Khawaja FI, Mahrous AR: Life-threatening severe immune thrombocytopenia after alpha-interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1996; 91:821-822.
41. Lopez Morante AJ, Saez-Royuela F, Casanova Valero F, Yuguero del Moral L, Martin Lorente GL, Ojeda Gimenez C, et al: Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C. Am J Gastroenterol 1992; 87:809-810.
42. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng J, Zacherl J, et al: Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28:1424-1429.
43. Torraceli F, Rosati S, Scuderi M, Laconi F, Picconi R, Laghi V: Leucocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45:1748-1752.